Home > Boards > US Listed > Biotechs >

Shire Plc (SHPG)

Add SHPG Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 9/16/2019 8:47:53 AM - Followers: 2 - Board type: Free - Posts Today: 0

Business Summary  

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#18   http://finance.yahoo.com/news/announcement-notice-shire-abbvie-board-234400720.h PennyStock Alert 09/16/19 08:47:53 AM
#17   Gawd I love this stock!!!!! Thank you SHPG rising 05/14/18 10:30:16 AM
#16   Ok figured out - ADR on SHIRE is rising 05/08/18 09:02:21 AM
#15   So how does the Shire shareholder make out rising 05/08/18 08:06:48 AM
#14   Ok so takeda is buying shire. So how rising 05/08/18 06:47:07 AM
#13   Riding and Raising that BULL flag since End rising 04/23/18 12:17:57 PM
#12   BEast Mode!! You cant buy out the IRISH! rising 04/20/18 01:16:55 PM
#11   Dip and rip baby! Great news no BUYOUT rising 04/19/18 09:41:17 AM
#10   Looking GREAT SHPG!!! rising 04/18/18 11:52:01 AM
#8   Shire shareholders approve $32 bln Baxalta merger (5/27/16) Enterprising Investor 05/27/16 09:12:24 AM
#7   Baxalta Shareholders Vote to Approve Combination (5/27/16) Enterprising Investor 05/27/16 09:07:04 AM
#6   Baxalta Announces Date for Special Meeting of Stockholders Enterprising Investor 05/19/16 10:58:43 AM
#5   Not only is Valeant Pharmaceuticals (NYSE:VRX) reportedly prepping [SMART MONEY] 02/13/15 02:32:35 AM
#4   ABBV BoD recommends dropping SHPG merger: #msg-107254974. DewDiligence 10/16/14 09:03:29 AM
#3   ABBV wavering on SHPG tax-inversion merger: DewDiligence 10/14/14 07:56:43 PM
#2   Annotations on phase-2b studies of ABT-493/ABT-530: #msg-106413637. DewDiligence 09/18/14 09:04:52 PM
#1   Shire Plc. [$SHPGF] due diligence stocktrademan 07/06/14 08:42:53 AM